RHHBF News and Press, Roche Holding Ltd

2024-06-26 14:05:02 ET Summary Greenwich LifeSciences, Inc. approaches enrollment completion for the phase 3 Flamingo-01 study, using GLSI-100 for the treatment of patients with HER2/neu positive breast cancer, with full enrollment expected by the end of 2024. A prior phase 2b stu...

2024-06-26 09:10:26 ET More on Sarepta Therapeutics Sarepta Therapeutics: Pushing The Edge And Creating The Horizon Sarepta Therapeutics: Why Today's Rally On DMD Drug Label Expansion Won't Last Sarepta Therapeutics: Navigating Elevidys Upside Potential Trend...

2024-06-25 17:50:06 ET Summary Roche Holding AG stock has seen a 13% price rise in the past month following positive trial results for its obesity treatment. Weight management and associated diseases like diabetes have huge potential, as seen from the examples of Novo Nordisk and ...

2024-06-20 10:52:39 ET More on Tempest Therapeutics Tempest Therapeutics: Multiple 2024 Catalysts Make This A Must Watch Tempest Therapeutics reports Q1 results Seeking Alpha’s Quant Rating on Tempest Therapeutics Historical earnings data for Tempest T...

2024-06-18 16:03:19 ET Summary Roche continues to face challenges tied to lackluster revenue and profit outlook, questionable pipeline, and an underperforming diagnostics business. Roche spends aggressively on its pipeline (R&D and M&A) and is more successful than peers in...

2024-06-18 11:26:22 ET Summary Novo Nordisk is a growth stock that continues to pleasantly surprise me and investors with the pace of its development of product candidates for the treatment of endocrine diseases. The company's share price reflects optimism about its diabetes franc...

2024-06-18 10:15:24 ET More on Roche Holding Roche Is Joining The Obesity Party But Questions Remain Emerging Leaders: Roche And Viking Therapeutics In The Obesity Treatment Race Roche: Targeting Mega-Money Obesity Markets After Sharing Stunning Weight Loss Data ...

2024-06-17 13:29:18 ET Summary Sarepta Therapeutics submitted a request to the FDA for label expansion of Elevidys, with a response expected by June 21st. Roche initiated the process for Elevidys marketing authorization application in Europe, expected to be completed by H1 2024. ...

2024-06-14 13:26:47 ET Summary Disc Medicine, Inc. released positive results from the phase 2 AURORA study, using bitopertin for the treatment of patients with EPP and XLP. Potential FDA feedback to initiate a pivotal study using bitopertin for the treatment of patients with EPP a...

2024-06-14 10:24:55 ET Summary Structure Therapeutics Inc. shares surged over 50% on positive GSBR-1290 data, competing with other oral GLP-1R clinical rivals. However, GSBR-1290's efficacy at week 12 fell below Novo Nordisk's amycretin, but still competitive in the obesity treatm...